More than 1.5 billion people around the world are infected with soil-transmitted helminths (STHs), parasitic worms that damage their health and are a leading cause of maln
GSK will invest around £1 billion ($1.2 billion) over a 10-year period to speed up R&D on infectious diseases that mainly impact lower-income countries.
Professor Paul Kaye from the University of York, whose research team was recently granted €8 million to help reduce the burden of leishmaniasis in African countries, takes us through the lo
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh